Tiziana Life Sciences Ltd. Common Shares (TLSA)
Stock · NASDAQ · Health Care
$1.06as of 10/16/2026
Price chart
Active signals
TLSA Signal Track Record
How signals performed across all stocks →What TLSA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -3.9% | 37% | September 23, 2026 |
| Bollinger Band Breakout | 24 | -8.8% | 25% | September 30, 2026 |
| Bollinger Band Breakdown | 22 | +4.4% | 64% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -7.4% | 25% | May 20, 2026 |
| Any 20-session window (baseline) | -3.1% | 41% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TLSA
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 10
- Website
- www.tizianalifesciences.com/
Fundamentals
- 1-day range
- $1.03$1.1
- Market cap
- $123.99M
- P/E (trailing)
- —
- P/E (forward)
- -5.82
- EPS (trailing)
- $-0.16
- Dividend yield
- —
- Beta
- 0.39
- Avg. volume
- 768.2K
Forecasts
2 analyst ratings
Tiziana Life Sciences Ltd. Common Shares Competitors
Chosen by industry and closest market cap.
- TLSATiziana Life Sciences Ltd. Common Shares$1.05▲ 0.00%Market cap $123.99MP/E —$0.7615$2.2
- IFRXInflaRx N.V. Common Stock$1.32▼ 8.33%Market cap $124.34MP/E —$0.7984$2.95
- GNLXGenelux Corporation Common Stock$2.42▼ 2.42%Market cap $121.07MP/E —$2.29$8.54
- SPRBSpruce Biosciences Inc. Common Stock$39.65▼ 4.39%Market cap $127.76MP/E —$38.06$179.95
- PMNProMIS Neurosciences Inc. Common Shares (ON)$8.15▼ 6.32%Market cap $119.54MP/E —$6.27$27.4
- BGMBGM Group Ltd. Class A Ordinary Shares$8.65▲ 0.70%Market cap $118.62MP/E —$6.45$303
- YARWYarrow Bioscience Inc. Common Stock$18.31▼ 8.45%Market cap $116.71MP/E —$18.16$44.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TLSA Tiziana Life Sciences Ltd. Common Shares | $123.99M | — | $1.05 | ▲ 0.00% | $0.7615$2.2 |
| IFRX InflaRx N.V. Common Stock | $124.34M | — | $1.32 | ▼ 8.33% | $0.7984$2.95 |
| GNLX Genelux Corporation Common Stock | $121.07M | — | $2.42 | ▼ 2.42% | $2.29$8.54 |
| SPRB Spruce Biosciences Inc. Common Stock | $127.76M | — | $39.65 | ▼ 4.39% | $38.06$179.95 |
| PMN ProMIS Neurosciences Inc. Common Shares (ON) | $119.54M | — | $8.15 | ▼ 6.32% | $6.27$27.4 |
| BGM BGM Group Ltd. Class A Ordinary Shares | $118.62M | — | $8.65 | ▲ 0.70% | $6.45$303 |
| YARW Yarrow Bioscience Inc. Common Stock | $116.71M | — | $18.31 | ▼ 8.45% | $18.16$44.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027benzinga · 10/16/2026
- Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapyYahoo · 9/30/2026
- MARKETS LIVE: US stock futures edge lower as investors await inflation dataYahoo · 9/30/2026
- Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)Yahoo · 9/30/2026
- Tiziana Life Sciences doses first ALS patients in Phase 2a Foralumab trialYahoo · 9/29/2026
- Tiziana doses first three patients in ALS trial of nasal antibody foralumabYahoo · 9/28/2026
- Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal ForalumabYahoo · 9/28/2026
- Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical TrialBenzinga · 9/28/2026
- Tiziana Life Sciences completes patient visits in Phase 2a MS drug trialYahoo · 9/21/2026
Insider Activity
Insider Actions →- Ivor Elrifi · August 15, 2026 · Option Exercise1.05M
- Ivor Elrifi · August 5, 2026 · Buy237.6K @ $1
- Ivor Elrifi · August 4, 2026 · Buy83.8K @ $0.97
- Ivor Elrifi · August 3, 2026 · Buy667.0K @ $1
- Gabriele M. Cerrone · July 21, 2026 · Buy42.4K @ $0.99
- Gabriele M. Cerrone · July 21, 2026 · Grant42.4K @ $0.99
- Gabriele M. Cerrone · June 12, 2026 · Buy15.0K @ $1.11
- Gabriele M. Cerrone · June 12, 2026 · Grant15.0K @ $1.11
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
TLSA Doses First ALS Patients, Completes MS Trial Visits
Tiziana Life Sciences has started dosing patients in its intranasal foralumab ALS trial, with the first three participants receiving the first dose. The company also completed patient visits in its Phase 2a multiple sclerosis trials, including the INFORM‑MS study, and the last patient finished the final visit. Topline results from the MS trial are expected in October, which will give insight into the drug’s safety and effectiveness.
TLSA Doses First ALS Patients, Completes MS Trial Visits. Tiziana Life Sciences has started dosing patients in its intranasal foralumab ALS trial, with the first three participants receiving the first dose. The company also completed patient visits in its Phase 2a multiple sclerosis trials, including the INFORM‑MS study, and the last patient finished the final visit. Topline results from the MS trial are expected in October, which will give insight into the drug’s safety and effectiveness.